As shown in Table 5, the main effect of CSFP and amyloid/tau/neurodegeneration (ATN) status in all patients (n = 132) was statistically significant, but no differences were found between AD and LBD patients. The gene discussed is MAPT; the disease is oculocutaneous albinism type 1.